Clinical efficacy of EGFR-TKIs for advanced squamous-cell lung cancer patients with EGFR mutations
10.3969/j.issn.1000-8179.2016.24.063
- VernacularTitle:EGFR-TKIs在晚期EGFR受体突变肺鳞癌患者中的临床应用
- Author:
Hongbo WU
;
Mingzhi LI
;
Liang SHI
;
Hong TAO
;
Junfang TANG
;
Zhe LIU
- Keywords:
epidermal growth factor receptor;
tyrosine kinase inhibitors;
squamous-cell lung cancer;
mutation
- From:
Chinese Journal of Clinical Oncology
2016;43(24):1103-1105
- CountryChina
- Language:Chinese
-
Abstract:
Abstrac Objective:To investigate the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of squamous-cell lung cancer patients with EGFR mutations. Methods:We screened out seven patients who were diag-nosed with EGFR mutations and received EGFR-TKIs, such as gifitinib or erlotinib, from 2,317 squamous-cell lung cancer patients treat-ed at the Beijing Chest Hospital from January 2010 to July 2016. Results:After using EGFR-TKIs, the objective response rate was 42.9%, the disease control rate was 100%, and the median progression-free survival was 6.1 months. Conclusion:EGFR-TKIs exert a certain clinical curative effect on patients with EGFR mutations in squamous-cell lung cancer. However, given that only seven cases are pre-sented in this research group, more cases are needed for further research to verify the above conclusion.
